Analysis of response to neoadjuvant chemotherapy (NCT) with doxorubicin plus cyclophosphamide followed by paclitaxel (AC- T) in triple negative locally advanced breast cancer (LABC) in Brazil

被引：0
|
作者：
Nunes, J. S. [1 ]
Tsunoda, A. T. [1 ]
Viana, L. S. [1 ]
Souza, F. H. [1 ]
Castro, N. [1 ]
Hohmann, J. [1 ]
Serrano, S. V. [1 ]
机构：
[1] Barretos Canc Hosp, Barretos, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.11551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11551
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Doxorubicin (Adriamycin, A) plus paclitaxel (T) followed by weekly paclitaxel (wT) as primary chemotherapy for women with locally advanced breast cancer (LABC).
    Zambetti, M
    Mariani, G
    Citterio, G
    Valagussa, P
    Greco, M
    Tomasic, G
    Lozza, L
    Piotti, P
    Gianni, L
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S110 - S110
  • [2] Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer
    Snider, Jessica N.
    Young, Robyn R.
    Schwartzberg, Lee Steven
    Allen, Jeffrey Warren
    Javed, Yasir Ahmed
    Jahanzeb, Mohammad
    Sachdev, Jasgit C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Prolonged primary chemotherapy (PC) with doxorubicin (A) plus paclitaxel (T) followed by weekly paclitaxel (AT&T) in women with inoperable locally advanced breast cancer (LABC).
    Zambetti, M
    Mariani, G
    Buglione, M
    Greco, M
    Bergonzi, S
    Tomasic, G
    Lozza, L
    Piotti, P
    Valagussa, P
    Gianni, L
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 23 - 23
  • [4] Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide plus /- Trastuzumab Followed by Docetaxel in Locally Advanced Breast Cancer (LABC)
    Tuxen, M. K.
    Cold, S.
    Tange, U. B.
    Soendergaard, S. B.
    Nielsen, D. L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S173 - S173
  • [5] Neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negative breast cancer.
    Snider, J. N.
    Allen, J. W.
    Young, R.
    Schwartzberg, L.
    Javed, Y.
    Jahanzeb, M.
    Sachdev, J. C.
    [J]. CANCER RESEARCH, 2012, 72
  • [6] Additional metabolic effects at the neoadjuvant chemotherapy (NCT) of locally advanced breast cancer (LABC).
    Abramova, Natalya A.
    Vladimirova, Liubov Yu
    Shikhliarova, Alla I.
    Storozhakova, Anna E.
    Kova, Valeriya S. Myag
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Breast conserving surgery after neoadjuvant chemotherapy paclitaxel plus doxorubicin vs fluorouracil plus doxorubicin plus cyclophosphamide in locally advanced breast cancer.
    Semlglazov, VF
    Bojok, AA
    Arsumanov, AS
    Ivanova, OA
    Ivanov, VG
    Semlglazov, VV
    Pozharissky, KM
    Topuzov, AE
    Nurgaziev, KS
    Paltuev, KS
    Petrov, RM
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S52 - S52
  • [8] IMMUNOHISTOCHEMICAL PREDICTORS OF PATHOLOGICAL RESPONSE IN PATIENTS WITH LOCALLY ADVANCED BREAST CANCER (LABC) UNDERGOING PACLITAXEL-BASED NEOADJUVANT CHEMOTHERAPY (NCT)
    De Rosa, G.
    Montemurro, F.
    Redana, S.
    Ponzone, R.
    Martincich, L.
    Gatti, M.
    Sarotto, I.
    Biglia, N.
    Risio, M.
    Sismondi, P.
    Aglietta, M.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 13 - 14
  • [9] Platinum compounds (PLcs) added to standard adjuvant or neoadjuvant regimen of doxorubicin plus cyclophosphamide (AC), followed by weekly paclitaxel (wP) in triple negative (TN), HER 2-neu positive (HER 2+) or locally advanced breast cancer (LABC)
    Vassilaki, M.
    Sioulas, A.
    Tsantekidou, M.
    Klitsa, A.
    Desses, N.
    Georgakopoulos, C.
    Kosmidis, C.
    Tsionou, C.
    Parassiris, V.
    Xepapadakis, G.
    [J]. BREAST, 2011, 20 : S66 - S66
  • [10] Neoadjuvant bevacizumab with weekly nanoparticle albumin bound nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer.
    Sachdev, J. C.
    Kronish, L. E.
    West, S.
    Schwartzberg, L.
    Jahanzeb, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345